Recalcitrant Cutaneous Warts Treated With Recombinant Quadrivalent Human Papillomavirus Vaccine (Types 6, 11, 16, and 18) in a Developmentally Delayed, 31-Year-Old White Man
Open Access
- 1 May 2010
- journal article
- case report
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 146 (5), 475-477
- https://doi.org/10.1001/archdermatol.2010.71
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial resultsVaccine, 2008
- Human papillomavirus vaccines and the potential for cross-protection between related HPV typesGynecologic Oncology, 2007
- Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)MMWR. Recommendations and Reports, 2007
- A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11Vaccine, 2006
- Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particlesVirology, 2006
- Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialThe Lancet, 2006
- Therapy of cutaneous human Papillomavirus infectionsDermatologic Therapy, 2004